IEX •
Healthcare •
Biotechnology •
Quote as of 08/14/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeIEX
Market Capitalization795.49 mln
Float40.72 mln
Earnings Date11/11/2026
Piotroski F-Score
3
/ 9
Below average
1-Year Forecast
21.62
Strong upside
Relative Strength
97
/ 100
Top performer
Debt / Equity
0.00
Debt-free
ROE
-31.63
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Climb Bio Inc. is a clinical-stage biotechnology company based in Wellesley Hills, Massachusetts, dedicated to creating treatments for patients with immune-mediated diseases. Its primary drug candidate, budoprutug, is an antibody that targets B-cell activity and is currently being tested in multiple clinical trials for conditions such as membranous nephropathy, immune thrombocytopenia, and lupus. The company is also advancing an early-stage antibody therapy called CLYM116, aimed at treating IgA nephropathy and related conditions. Formerly known as Eliem Therapeutics, the company rebranded as Climb Bio in October 2024.
